Adenovirus-mediated human interleukin-12(NCI)

Johnson & Johnson (J&J) received emergency use authorization from the Food and Drug Administration for its single-dose, adenovirus vector COVID-19 vaccine (Ad26.COV2.S) on February 27, 2021. As with the 2 mRNA vaccines that have also received emergency use authorization, local and systemic side effects were common and seen in over 50% of patients.1 No rashes other than injection-site reactions and delayed hypersensitivity reactions, now known as “COVID arm,” were reported, according to J&J's phase 3 interim analysis. Other than 5 reported cases of urticaria, there were no reports of “rash” or “dermatitis.”2 At present, there is a paucity of data on skin eruptions from the J&J COVID-19 vaccine. We report the case of an 83-yearold woman with a widespread erythematous annular eruption that resolved after a week of treatment with antihistamines and mid-potency topical steroids.